Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04852887 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Study acronym: DEBRA
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 54 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 7, 2021 to Jun 23, 2021v54
  2. Primary completion pushed from Apr 2026 to Apr 8, 2031v53
  3. Site details revised at 18 of 832 sitesv52
  4. Site details revised at 21 of 832 sitesv51
  5. Study sites: 828 to 832 Primary completion date: Jan 2026 to Apr 2026v50 Show 1 more changeShow less
    • Primary completion date: Jan 2026 to Apr 2026
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites revised (828)v49 See this version in full on ClinicalTrials.gov ↗
  2. Study sites: 826 to 828v48
  3. Study sites: 823 to 826v47
  4. Study sites: 812 to 823v46
  5. Study sites: 809 to 812v45
  6. Study sites: 808 to 809v44
  7. Study sites: 805 to 808v43
  8. Study sites: 801 to 805v42
  9. Study sites: 798 to 801v41
  10. Study sites: 794 to 798v40
  11. Study sites: 787 to 794v39
  12. Study sites: 776 to 787v38
  13. Study sites: 769 to 776v37
  14. Study sites: 753 to 769v36
  15. Study sites: 748 to 753v35
  16. Study sites: 740 to 748v34
  17. Study sites: 735 to 740v33
  18. Study sites: 714 to 735v32
  19. Study sites: 708 to 714v31
  20. Study sites: 692 to 708v30
  21. Study sites: 684 to 692v29
  22. Study sites: 668 to 684v28
  23. Study sites: 660 to 668v27
  24. Eligibility criteria expanded, about 135 wordsv26 See this version in full on ClinicalTrials.gov ↗
  25. Study sites: 654 to 660v25
  26. Study sites: 653 to 654v24
  27. Study sites: 639 to 653v23
  28. Study sites: 633 to 639v22
  29. Study sites: 625 to 633v21
  30. Study sites: 617 to 625v20
  31. Study sites: 599 to 617v19
  32. Study sites: 577 to 599v18
  33. Study sites: 557 to 577v17
  34. Study sites: 527 to 557v16
  35. Study sites: 513 to 527v15
  36. Study sites: 487 to 513v14
  37. Study sites: 468 to 487v13
  38. Study sites: 444 to 468v12
  39. Study sites: 432 to 444v11
  40. Study sites: 418 to 432v10
  41. Study sites: 397 to 418v9
  42. Study sites: 389 to 397v8
  43. Study sites: 372 to 389v7
  44. Study sites: 339 to 372v6
  45. Study sites: 329 to 339v5
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
NRG Oncology
67 trials monitored
See 5 trials at risk
Breast Cancer
5,213 trials monitored
See 271 trials at risk
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Trial Details
NCT Number NCT04852887
Lead Sponsor NRG Oncology
Collaborators: National Cancer Institute (NCI)
Conditions Stage I Breast Cancer
Enrollment 1,670 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov